ADC Therapeutics (ADCT) Stock Price, News & Analysis

Company Overview

ADC Therapeutics SA is a clinical-stage biopharmaceutical company focused on the discovery and development of highly targeted antibody-drug conjugates (ADCs) designed to treat hematological malignancies such as non-Hodgkin lymphoma and acute myeloid leukemia. By marrying the specificity of monoclonal antibodies with potent cytotoxic payloads, the company aims to maximize tumor cell eradication while limiting off-target toxicity.

At the core of ADC Therapeutics’ portfolio is loncastuximab tesirine-lpyl, a CD19-directed ADC that received accelerated approval from the U.S. Food and Drug Administration for the treatment of adults with relapsed or refractory large B-cell lymphoma. In addition to this approved asset, the company’s pipeline features multiple next-generation ADC candidates targeting novel antigens, several of which are advancing through late-stage clinical trials.

Founded in 2012 as a spin-out from Heidelberg University, ADC Therapeutics is headquartered in Lausanne, Switzerland, with additional offices in London and New York. Its global footprint spans Europe and North America, encompassing clinical research sites and manufacturing partnerships that support multi-regional trials and scaled production of its specialized conjugates.

The company is led by a management team with deep expertise in antibody engineering, oncology drug development and regulatory affairs. Through collaborations with academic institutions and industry partners, ADC Therapeutics seeks to accelerate its translational research efforts and bring innovative ADC therapies to patients battling blood cancers.

Key Stats

• Today's Range: $4.02 to $4.20
• 50-Day Range: $2.68 to $4.63
• 52-Week Range: $1.05 to $4.74
• Volume: 734,454 shs
• Average Volume: 1.34 million shs
• Market Capitalization: $457.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.50
• Consensus Rating: Moderate Buy

ADC Therapeutics Stock Analysis - MarketRank™

ADC Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 560th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

ADC Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

ADC Therapeutics has a consensus price target of $7.50, representing about 84.3% upside from its current price of $4.07.

Amount of Analyst Coverage

ADC Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ADC Therapeutics are expected to grow in the coming year, from ($1.69) to ($1.52) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ADC Therapeutics is -2.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ADC Therapeutics is -2.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.71% of the outstanding shares of ADC Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

ADC Therapeutics has a short interest ratio ("days to cover") of 6.5.

Change versus previous month

Short interest in ADC Therapeutics has recently increased by 30.22%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ADC Therapeutics does not currently pay a dividend.

Dividend Growth

ADC Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.71% of the outstanding shares of ADC Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

ADC Therapeutics has a short interest ratio ("days to cover") of 6.5.

Change versus previous month

Short interest in ADC Therapeutics has recently increased by 30.22%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.52

News Sentiment

ADC Therapeutics has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 18 news articles for ADC Therapeutics this week, compared to 3 articles on an average week.

Search Interest

16 people have searched for ADCT on MarketBeat in the last 30 days. This is an increase of 220% compared to the previous 30 days.

MarketBeat Follows

1 people have added ADC Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ADC Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.40% of the stock of ADC Therapeutics is held by insiders.

Percentage Held by Institutions

41.10% of the stock of ADC Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ADCT Stock Analysis - Frequently Asked Questions

How have ADCT shares performed this year?

ADC Therapeutics' stock was trading at $1.99 at the beginning of the year. Since then, ADCT shares have increased by 104.5% and is now trading at $4.07.

How were ADC Therapeutics' earnings last quarter?

ADC Therapeutics SA (NYSE:ADCT) issued its earnings results on Tuesday, August, 12th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.36) by $0.14. The company earned $18.84 million during the quarter, compared to analyst estimates of $17.82 million.
Read the conference call transcript.

When did ADC Therapeutics IPO?

ADC Therapeutics (ADCT) raised $126 million in an IPO on Friday, May 15th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Securities and Cowen and Company acted as the underwriters for the IPO.

Who are ADC Therapeutics' major shareholders?

Top institutional shareholders of ADC Therapeutics include Ethic Inc. (0.01%) and Voya Investment Management LLC (0.01%). Insiders that own company stock include Redmile Group, Llc, Ameet Mallik and Robert Azelby.
View institutional ownership trends.

How do I buy shares of ADC Therapeutics?

Shares of ADCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ADC Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ADC Therapeutics investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 10/18/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:ADCT
• CIK: 1771910
• Web: www.adctherapeutics.com
• Phone: 41-21-653-0200
• Fax: N/A
• Employees: 310
• Year Founded: 2010

Price Target and Rating

• Average Price Target for ADC Therapeutics: $7.50
• High Price Target: $10.00
• Low Price Target: $5.00
• Potential Upside/Downside: +84.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.57)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$157.85 million
• Net Margins: -220.00%
• Pretax Margin: -218.13%
• Return on Equity: N/A
• Return on Assets: -53.73%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.93
• Quick Ratio: 4.66

Sales & Book Value

• Annual Sales: $70.84 million
• Price / Sales: 6.46
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.10) per share
• Price / Book: -1.94

Miscellaneous

• Outstanding Shares: 112,500,000
• Free Float: 106,424,000
• Market Cap: $457.88 million
• Optionable: Optionable
• Beta: 1.99